50 completed. 50 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 50 | Completed 50 |
| Phase 2 | 14 | Completed 14 |
Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Test-retest Study With [18F]PI-2620 in PSP-RS and NDC [18F]-PI2620 - Progressive Supranuclear Palsy | Phase 1 | Completed | Life Molecular Imaging GmbH | 15 | 2022-03-10 | 2026-10-26 |
| Evaluation of [18F]APN-1607 as a PET Biomarker [18F] APN-1607 - Progressive Supranuclear Palsy, Healthy Volunteers | Phase 1 | Completed | Invicro | 12 | 2021-05-25 | 2025-02-20 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity [18F]-PI2620 - Alzheimer Disease, Progressive Supranuclear Palsy | Phase 1 | Completed | Life Molecular Imaging GmbH | 10 | 2020-11-12 | 2026-10-26 |
| A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) bepranemab, Placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | UCB Biopharma SRL | 25 | 2019-12-03 | 2023-12-01 |
| A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease KL1333, Placebo Oral Tablet - Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies | Phase 1 | Completed | Abliva AB | 72 | 2019-03-18 | 2021-10-20 |
| Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 ABBV-8E12 - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | AbbVie | 3 | 2018-04-17 | 2019-12-03 |
| Phase 1 Test-retest Evaluation of [18F]MNI-958 PET [18F]MNI-958 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Completed | Invicro | 16 | 2018-03-12 | 2020-02-17 |
| Adipose Stem Cells for Traumatic Spinal Cord Injury Autologous, Adipose derived Mesenchymal Stem Cells - Spinal Cord Injuries, Paralysis | Phase 1 | Completed | Mohamad Bydon | 10 | 2017-12-05 | 2022-08-30 |
| RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease RQ-00000010, Placebo - Parkinson's Disease, Gastroparesis | Phase 1 | Completed | Virginia Commonwealth University | 51 | 2016-06-01 | 2019-10-09 |
| Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy BIIB092, Placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | Biogen | 48 | 2015-10-02 | 2018-09-04 |
| Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Single dose C2N-8E12, Single dose placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | C2N Diagnostics | 32 | 2015-07-01 | 2017-07-26 |
| Young Plasma Transfusions for Progressive Supranuclear Palsy Fresh Frozen Plasma - Progressive Supranuclear Palsy | Phase 1 | Completed | University of California, San Francisco | 6 | 2015-05-01 | 2020-08-11 |
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Salsalate - Progressive Supranuclear Palsy | Phase 1 | Completed | Adam Boxer | 10 | 2015-04-01 | 2021-04-01 |
| Dose Escalation Study of AST-OPC1 in Spinal Cord Injury AST-OPC1 - Cervical Spinal Cord Injury, Spine Injury | Phase 1 / Phase 2 | Completed | Lineage Cell Therapeutics, Inc. | 25 | 2015-03-01 | 2021-07-14 |
| The Safety of ahSC in Chronic SCI With Rehabilitation Autologous human Schwann cells - Spinal Cord Injury, Paraplegia | Phase 1 | Completed | W. Dalton Dietrich | 8 | 2015-01-01 | 2019-08-14 |
| Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Flortaucipir F18, Brain PET scan - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 1 | Completed | Avid Radiopharmaceuticals | 29 | 2014-08-12 | 2020-08-28 |
| Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects Nizatidine, Lisinopril, Placebo - Gastroparesis | Phase 1 | Completed | Adil Bharucha | 24 | 2014-07-01 | 2015-04-30 |
| Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis TC-6499, Placebo - Gastroparesis | Phase 1 / Phase 2 | Completed | Targacept Inc. | 80 | 2014-06-01 | 2015-05-12 |
| Safety Study of TPI-287 to Treat CBS and PSP TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS) | Phase 1 | Completed | University of California, San Francisco | 44 | 2014-05-01 | 2020-04-15 |
Showing 20 of 50. Sign in to see all of them.
Supranuclear Palsy, Progressive (17) · Gastroparesis (15) · Quadriplegia (8) · Spinal Cord Injuries (8) · Paraplegia (6) · Stroke (6) · Hemiplegia (5) · Corticobasal Degeneration (4) · Alzheimer Disease (3) · Paresis (3) · Pick Disease of the Brain (3) · Diabetes Mellitus (2) · Nausea (2) · Parkinson Disease (2)
Pathological Conditions, Signs and Symptoms (50) · Signs and Symptoms (50) · Neurologic Manifestations (49) · Nervous System Diseases (36) · Central Nervous System Diseases (33) · Brain Diseases (25) · Cranial Nerve Diseases (19) · Basal Ganglia Diseases (18) · Eye Diseases (18) · Movement Disorders (18) · Neurodegenerative Diseases (18) · Ocular Motility Disorders (18) · Ophthalmoplegia (18) · Digestive System Diseases (15)
N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine (3) · ((18)F)PI-2620 (2) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2) · Constraint Induced Movement Therapy (2) · florbetapir (2) · Acetylcarnitine (1) · Acupuncture Therapy (1) · Body Piercing (1) · Buspirone (1) · Glucose (1) · Ketoconazole (1) · Levodopa (1) · Lisinopril (1) · Lithium (1) · Melatonin (1)
GlaxoSmithKline (5) · University of California, San Francisco (3) · Invicro (2) · Life Molecular Imaging GmbH (2) · W. Dalton Dietrich (2) · AbbVie (1) · Abliva AB (1) · Adam Boxer (1) · Adil Bharucha (1) · Avid Radiopharmaceuticals (1) · Biogen (1) · C2N Diagnostics (1) · Dr. Gabriel Zeilig (1) · Forest Laboratories (1) · Georgia Institute of Technology (1)
United States (34) · United Kingdom (6) · Germany (4) · Australia (3) · Canada (3) · Belgium (2) · Spain (2) · Denmark (1) · Israel (1) · Norway (1) · Singapore (1) · Sweden (1)
Adam Boxer, MD, PhD (3) · Allan Levi, MD, PhD (2) · Andrew Stephens, MD, PhD (2) · James Guest, MD, PhD (2) · Adam L. Boxer, M.D., Ph.D. (1) · Adil Bharucha, MBBS, MD (1) · Beatrice J Kiratli, PhD (1) · Chua Karen, MD (1) · Claire Henchcliffe, MD DPhil (1) · Dalton Dietrich, PhD (1) · Danna Jennings, MD (1) · David Russell, M.D., Ph. D (1)
PMID 19615045, PMID 19666345, PMID 19965145, PMID 21381984, PMID 21575185, PMID 21652288, PMID 22254998, PMID 22275632, PMID 22531737, PMID 22692932, PMID 22738299, PMID 22961573, PMID 23366834, PMID 23366943, PMID 23639598, PMID 23844986, PMID 24119615, PMID 24284925, PMID 25148846, PMID 25570772, PMID 26084322, PMID 28225648, PMID 28782145, PMID 29760737, PMID 31122495, PMID 31710340, PMID 31785831, PMID 32493977, PMID 35364569, PMID 35901693, PMID 36772802, PMID 38561341, PMID 41389437
1RC1EB010915-01 (1), 2019 (1), K01HD069504 (1), P01DK068055 (1), R43AT004489 (1), UL1RR024150 (1)